Pharmacy benefit spending on oral chemotherapy drugs

Journal of Managed Care Pharmacy

Volumn 12, Issue 7, 2006, Pages 570-577

  Curtiss, Frederic R ^a  

^a Academy of Managed Care Pharmacy   (United States)

Author keywords

Budget forecasting; Chemotherapy drugs; Drug costs; Pharmacy benefits

Indexed keywords

ANTINEOPLASTIC AGENT; AZACITIDINE; CAPECITABINE; CARBOPLATIN; CISPLATIN; DASATINIB; DEXAMETHASONE; DOCETAXEL; ERLOTINIB; FLUOROURACIL; GEFITINIB; GEMCITABINE; IMATINIB; LENALIDOMIDE; MERCAPTOPURINE; PACLITAXEL; PLATINUM; PROTEIN TYROSINE KINASE INHIBITOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SORAFENIB; SUNITINIB; TABLOID; THALIDOMIDE; TIOGUANINE; UNCLASSIFIED DRUG; BENZENESULFONIC ACID DERIVATIVE; DEOXYCYTIDINE; DRUG DERIVATIVE; INDOLE DERIVATIVE; PIPERAZINE DERIVATIVE; PYRIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE; QUINAZOLINE DERIVATIVE; THIAZOLE DERIVATIVE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADVANCED CANCER; ARTICLE; BILLING AND CLAIMS; BREAST CANCER; CANCER; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; DATA BASE; DRUG COST; DRUG DOSE REDUCTION; DRUG INHIBITION; DRUG LABELING; DRUG MARKETING; ERYTHEMA NODOSUM LEPROSUM; GASTROINTESTINAL STROMAL TUMOR; GRAFT VERSUS HOST REACTION; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH INSURANCE; HUMAN; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; MONOTHERAPY; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; OUTPATIENT; OVERALL SURVIVAL; PHILADELPHIA 1 CHROMOSOME; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; REIMBURSEMENT; SKIN TOXICITY; TERATOGENICITY; TREATMENT FAILURE; TREATMENT RESPONSE; AMBULATORY CARE; ECONOMICS; FEE; NEOPLASM; ORAL DRUG ADMINISTRATION; STATISTICS; UNITED STATES; UTILIZATION REVIEW;

ADMINISTRATION, ORAL; AMBULATORY CARE; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; DEOXYCYTIDINE; DRUG COSTS; EMPLOYER HEALTH COSTS; FLUOROURACIL; HEALTH BENEFIT PLANS, EMPLOYEE; HUMANS; INDOLES; INSURANCE, PHARMACEUTICAL SERVICES; NEOPLASMS; PIPERAZINES; PRESCRIPTION FEES; PYRIDINES; PYRIMIDINES; PYRROLES; QUINAZOLINES; THALIDOMIDE; THIAZOLES; UNITED STATES;

EID: 34548620214     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2006.12.7.570     Document Type: Article

References (39)

1. U.S. Food and Drug Administration, Office of Oncology Drug Products (OODP). FDA approves lenalidomide oral capsules (Revlimid) for use in combination with dexamethasone in patients with multiple myeloma. Available at: http://www.fda.gov/cder/Offices/OODP/whatsnew/lenalidomide.htm. Accessed August 29, 2006.
2. Anand G. Celgene to price cancer medicine at $6,195 a month. Wall Street Journal. July 1, 2006:A4.
3. Prescribing information from the product label for lenalidomide (Revlimid) reported in Drug Facts and Comparisons (Clinisphere version ISBN 1-57439-036-8). St. Louis, MO: Wolters, Kluwer Health, Inc. August 2006. Accessed August 29, 2006.
4. U.S. Food and Drug Administration. FDA Talk Paper - FDA approves Xeloda for breast cancer. Available at: http://www.fda.gov/bbs/topics/ ANSWERS/ANS00864.html. Accessed August 30, 2006.
5. McCann J. MAbs take spotlight at hematology meeting. Drug Top. January 15, 2001:45.
6. MedlinePlus. Medical encyclopedia. Chronic myelogenous leukemia (CML). Available at: http://www.nlm.nih.gov/medlineplus/ency/article/000570.htm. Accessed September 1, 2006.
7. Fuhrman V. Novartis seeks speedy approval of 'smart' cancer drug, Glivec. Wall Street Journal. March 1, 2001:B14.
8. Anonymous. FDA clears novel Novartis cancer drug. Wall Street Journal. May 11, 2001:A3.
9. Anonymous. FDA gives a green light to Gleevec cancer drug. Wall Street Journal. February 4, 2002:B5.
10. Gastrointestinal stromal tumor. Wikipedia. Available at: http://en.wikipedia.org/wiki/Gastrointestinal_stromal_tumor. Accessed September 1, 2006.
11. Antineoplastic agents, protein-tyrosine kinase inhibitors, imatinib mesylate. Drug Facts and Comparisons, Clinisphere version ISBN 1-57439-036-8), August 2006. St. Louis, MO: Wolters, Kluwer Health, Inc. Accessed September 1, 2006.
12. Antineoplastic agents, epidermal growth factor receptor inhibitors, gefitinib oral. Drug Facts and Comparisons, Clinisphere version ISBN 1-57439-036-8, August 2006. St. Louis, MO: Wolters, Kluwer Health, Inc. Accessed August 29, 2006.
13. U.S. Food and Drug Administration. Gefitinib (Iressa) product label, May 6, 2004 revision. Available at: http://www.fda.gov/cder/foi/label/2004/ 21399slr003_Iressa_lbl.pdf. Accessed Sept 2, 2006.
14. U.S. Food and Drug Administration. FDA Alert [June 2005]. Gefitinib (marketed as Iressa) information. Available at: http://www.fda.gov/cder/drug/ infopage/gefitinib/default.htm. Accessed September 2, 2006.
15. U.S. Food and Drug Administration. FDA News. FDA approves new drug for the most common type of lung cancer - drug shows survival benefit. November 19, 2004. Available at: http://www.fda.gov/bbs/topics/news/2004/ NEW01139.html. Accessed September 3, 2006.
16. Antineoplastic agents, epidermal growth factor receptor inhibitors, erlotinib oral. Drug Facts and Comparisons, Clinisphere version ISBN 1-57439-036-8, August 2006. St. Louis, MO: Wolters, Kluwer Health, Inc. Accessed September 3, 2006.
17. U.S. Food and Drug Administration. Oncology tools. Approved claims for 2005. Available at: http://www.accessdata.fda.gov/scripts/cder/onctools/ yearlistclaim.cfm?Approv_Date=2005. Accessed September 3, 2006.
18. Shepherd FA, Rodrigues Pereira J, et al, for the National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353:123-32.
19. U.S. Food and Drug Administration. FDA News. FDA approves new treatment for advanced kidney cancer. December 20, 2005. Available at: http://www.fda.gov/bbs/topics/NEWS/2005/NEW01282.html. Accessed September 3, 2006.
20. U.S. Food and Drug Administration. FDA News. FDA approves new treatment for gastrointestinal and kidney cancer. January 26, 2006. Available at: http://www.fda.gov/bbs/topics/news/2006/NEW01302.html. Accessed September 3, 2006.
21. Antineoplastic agents, multikinase inhibitor, sorafenib oral. Drug Facts and Comparisons, Clinisphere version ISBN 1-57439-036-8, August 2006. St. Louis, MO: Wolters, Kluwer Health, Inc. Accessed September 3, 2006.
22. Antineoplastic agents, protein-tyrosine kinase inhibitors, sunitinib malate oral. Drug Facts and Comparisons, Clinisphere version ISBN 1-57439-036-8, August 2006. St. Louis, MO: Wolters, Kluwer Health, Inc. Accessed September 3, 2006.
23. U.S. Food and Drug Administration. Office of Oncology Drug Products (OODP). FDA approves Thalomid (thalidomide) to treat multiple myeloma. Available at: http://www.fda.gov/cder/Offices/OODP/whatsnew/ thalidomide.htm. Accessed August 29, 2006.
24. U.S. Food and Drug Administration. Thalidomide information. FDA announces approval of drug for Hansen's Disease (leprosy) side effect: imposes unprecedented author to restrict distribution. Available at: http://www.fda.gov/ cder/news/thalinfo/default.htm. Accessed August 29, 2006.
25. Biologic and immunologic agents, immunomodulators, thalidomide oral. Drug Facts and Comparisons, Clinisphere version ISBN 1-57439-036-8, August 2006. St. Louis, MO: Wolters, Kluwer Health, Inc. Accessed August 29, 2006.
26. U.S. Food and Drug Administration. Office of Oncology Drug Products (OODP). FDA approves dasatinib (Sprycel) for use in the treatment of adults with chronic phase, accelerated phase, or myeloid or lymphoid blast phase chronic myeloid leukemia. Available at: http://www.fda.gov/cder/Offices/OODP/ whatsnew/dasatinib.htm. Accessed September 1, 2006.
27. Myelodysplastic syndrome. Leukemia Research Foundation. Available at: http://www.lrf.org.uk/en/1/infdispatmye.html. Accessed September 2, 2006.
28. Antineoplastic agents, DNA demethylation agents, azacitidine. Drug Facts and Comparisons, Clinisphere version ISBN 1-57439-036-8, August 2006. St. Louis, MO: Wolters, Kluwer Health, Inc. Accessed August 29, 2006.
29. Myelodysplastic Foundation. Facts you should know about Medicare Part D. Available at: http://www.mds-foundation.org/articles/medicare-facts-part-d. htm#facts. Accessed September 2, 2006.
30. Ramsey SD, Clarke L, Kamath TV, Lubeck D. Evaluation of erlotinib in advanced non-small cell lung cancer: impact on the budget of a U.S. health insurance plan. J Manag Care Pharm. 2006;12(6):472-78. Available at: http://www.amcp.org/data/jmcp/form_472-478.pdf. Accessed August 31, 2006.
31. Antineoplastic agents, monoclonal antibodies, traztuzumab. Drug Facts and Comparisons, Clinisphere version ISBN 1-57439-036-8, August 2006. St. Louis, MO: Wolters, Kluwer Health, Inc. Accessed August 29, 2006.
32. Homberg M, Zanni GR. Bringing hope home with oral antineoplastic agents. Pharm Times. March 2005. Available at: https://secure.pharmacytimes. com/lessons/200503-02.asp. Accessed September 3, 2006.
33. Partridge AH, Avorn J, Wang PS, Winer EP. Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst. 2002;94(9):652-61.
34. O'Neill VJ, Twelves CJ. Oral cancer treatment: developments in chemotherapy and beyond. Br J Cancer. 2002;87(9):933-37.
35. Wick JY. Senior clinical research pharmacist, National Cancer Institute, Bethesda, MD [personal communication].
36. Antineoplastic agents, epidermal growth receptor factor inhibitors, erlotinib. Drug Facts and Comparisons, Clinisphere version ISBN 1-57439-036-8, August 2006. St. Louis, MO: Wolters, Kluwer Health, Inc. Accessed August 29, 2006.
37. Revlimid (lenalidomide) product label, 5 mg 10 mg, 15 mg, and 25 mg capsules. U.S. Food and Drug Administration. Available at: http://www.fda.gov/ medwatch/safety/2006/Jun_PIs/Revlimid_PI.pdf. Accessed September 3, 2006.
38. Leight NB, Tsao WS, Zawuiza DL, Nematollahi M, Shepherd FA. A willingness-to-pay study of oral epidermal growth factor tyrosine kinase inhibitors in advanced non-small cell lung cancer. Lung Cancer. 2006;51(1):137-38.
39. Schrag D. The price tag on progress - chemotherapy for colorectal cancer. N Engl J Med. 2004;351:317-19.